IGF1R and breast cancer: After a median follow‐up period of 74.5 months (range, 17–117), the median disease‐free survival (DFS) was 28 months (range, 7–89) for patients with early breast cancer displaying both IGF1R(+) and IGF1R(−) CTCs, while DFS was not reached for those with exclusively IGF1R(+) CTCs (log‐rank test, P = 0.02) (Fig. 4A).